Nikola Topic makes Thunder debut after testicular cancer
Aggregated coverage · Methodology and corrections
Coverage first published:
Coverage updated:
Coverage
Nikola Topic makes Thunder debut after testicular cancer
Nikola Topic, who missed all of last season because of a knee injury and had not played this season after the cancer diagnosis, made his debut Thursday.
Publisher:ESPN NBA
Lead articleArticle published:Thunder's Nikola Topić to make his NBA debut on Thursday after cancer battle
Topić has not played an NBA game since being drafted with the 12th overall pick in the 2024 draft.
Publisher:Yahoo Sports NBAArticle published:
Nikola Topic makes his NBA debut for the Thunder after testicular cancer diagnosis and chemotherapy
OKLAHOMA CITY (AP) — Nikola Topic made his NBA debut Thursday night for the Thunder after undergoing treatment for testicular cancer. The Serbian guard was the 12th pick in the 2024 NBA draft. He missed all of last season with a knee injury he suffered before the draft and all of this season after the cancer diagnosis during the preseason. He had a procedure in October, then underwent chemotherapy and worked his way back into shape. He entered the game Thursday against the Milwaukee Bucks lat...
Publisher:Yahoo Sports NBAArticle published:
Thunder's Nikola Topic Available To Make NBA Debut Thursday
Nikola Topic is not on the Thunder‘s injury report for Thursday’s game vs. Milwaukee, which means he’ll be active to potentially make his NBA regular season debut, notes Justin Martinez of The Oklahoman (subscriber link). The 12th overall pick in the 2024 draft, Topic missed the entire 2024/25 season due to a torn anterior cruciate […]
Publisher:Hoops RumorsArticle published:
The Thunder drafted Nikola Topic 12th in 2024. He played his first NBA minutes Thursday night
Nikola Topic made his NBA debut Thursday night. The Thunder drafted him 12th overall in 2024. He missed his rookie season with a knee injury. ...
Publisher:NBA Analysis NetworkArticle published:
Nikola Topić makes NBA debut for Thunder after testicular cancer treatment - Sportando
The 2024 No. 12 pick returns after surgery and chemotherapy, scores 2 points in a 110-93 loss to Milwaukee and receives a big ovation in Oklahoma City L'articolo Nikola Topić makes NBA debut for Thunder after testicular cancer treatment proviene da Sportando .
Publisher:SportandoArticle published:
Nikola Topić makes NBA debut with Thunder months after cancer diagnosis
Thunder guard Nikola Topić made his NBA debut against the Bucks on Thursday night, four months after he was diagnosed with cancer.
Publisher:Yahoo Sports NBAArticle published:
Thunder's Nikola Topic receives standing ovation in NBA debut after cancer battle
Topić finished the game with two points, 1 rebounds and 1 assists in 12 minutes in his first NBA game.
Publisher:Yahoo Sports NBAArticle published:
Nikola Topic officially makes NBA debut to roaring ovation from Thunder fans
Oklahoma City fans were proud to finally see Nikola Topic make his long-awaited NBA debut in the Thunder’s matchup against the Milwaukee Bucks on Thursday night. Topic entered the league when the Thunder selected him 12th overall in the 2024 NBA Draft. However, he has yet to make his debut due to serious injuries and […] The post Nikola Topic officially makes NBA debut to roaring ovation from Thunder fans appeared first on ClutchPoints .
Publisher:ClutchPointsArticle published:
Thunder’s Nikola Topic makes NBA debut after testicular cancer diagnosis
The reaction that Nikola Topić received captured the magnitude of the moment.
Publisher:Yahoo Sports NBAArticle published:
Thunder’s Nikola Topic makes NBA debut after testicular cancer diagnosis
The reaction that Nikola Topić received captured the magnitude of the moment.
Publisher:NY Post NBAArticle published:
Nikola Topic makes emotional NBA debut after cancer battle
Ousmane Dieng shines against his former team, but the night belongs to 20-year-old Nikola Topic The post Nikola Topic makes emotional NBA debut after cancer battle appeared first on Eurohoops .
Publisher:EuroHoopsArticle published:


Comments